PharmaShots | Incisive News in 3 Shots

Subscribe Now

Sumitomo Pharma

Sumitomo Pharma and Otsuka Failed to Meet its Primary Endpoints of Ulotaront in P-III Trials (DIAMOND 1 & 2) for Schizophrenia

Sumitomo Pharma and Otsuka Failed to Meet its Primary Endpoints of Ulotaront in P-III Trials (DIAMOND 1 & 2) for Schizophrenia

August 1, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us